Mack. I’ll get you answers in a bit. I have to go thru the criteria and time frames in the protocol. Remember all patients had the same protocol and time frames. CR treatment occurred for a specific amount of time IMO so the chart is very meaningful.
The drug produced a benefit in delayed onset and lower incidence, among other benefits. Your question seems odd. Does individual patient A derive a benefit from a drug that delays the onset of a hideous disease ( and perhaps severity)? Yes.
Market Data 
Markets 
AI
